ProfileGDS5678 / 1443976_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 62% 61% 61% 62% 60% 62% 61% 61% 61% 61% 61% 62% 58% 61% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.7164262
GSM967853U87-EV human glioblastoma xenograft - Control 23.6615261
GSM967854U87-EV human glioblastoma xenograft - Control 33.6517161
GSM967855U87-EV human glioblastoma xenograft - Control 43.678262
GSM967856U87-EV human glioblastoma xenograft - Control 53.5638460
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.7633462
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.7085661
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.6662561
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.638761
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.6567161
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.6627761
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.6567162
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.5300958
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.6629961